Advances in herpes prevention and treatment- vaccines and nanoparticles
Antigenics (AGEN) is a biotechnology company focusing on the development of cancer vaccines and autoimmune disorders. While there’s almost no research on the numbers, I’ve found that it’s a very small minority of the H+ population that disclose. Of 53 sexual partners, not a single one has disclosed to me. The Phase 2 study (designated as protocol C-400-02) has screened over 100 HSV-2 positive subjects and enrollment has been closed. Garo Armen, Chairman and CEO of Agenus, will present a corporate overview on Tuesday, January 10th from 9:15-9:30 am PST in the Windsor Room and a break out session will follow from 9:30-10:15 am. Data analyst. in November 2013 of results from its randomized, double-blind, Phase II study for HerpV for the treatment of herpes simplex virus-2 (HSV-2).
The majority of those patients showed a CD8+ T cell response. Agenus’ QS-21 Stimulon is a novel adjuvant that is incorporated into 17 vaccines currently in clinical development, including four GlaxoSmithKline (GSK) Phase 3 programs. Said Darke, and I hope that recurrent herpes simplex treatment in an hour one of us will be dead, I care not which. Also at Yale, Mark Saltzman, chair of the biomedical engineering department of the Yale School of Medicine, and researchers in his laboratory have been working to develop nanoparticles to decrease symptom severity and boost survival rates of mice with HSV-2, according to a Yale Daily News report. It will still crack open due to facial muscles all over the world there is no point in your system again. Agenus uses its heat shock protein platform for its Prophage Series of vaccines, which include Oncophage for Renal Cell Carminoma, G-100 for newly diagnosed Glioma, and G-200 for recurrent Glioma. This article will attempt to do just that.
These statements speak only as of the date of this call and Agenus undertakes no obligation to update or revise the statements. From above, it is evident why a powerful pharmaceutical company such as GlaxoSmithKline is partnered with Agenus. According to their news release, the study designated as protocol C-400-02 will enroll 75 HSV-2 positive subjects who have a history of frequent disease recurrences. In a four-arm, Phase 1 study, 35 HSV-2 seropositive patients received HerpV (designated in the study as AG-707 plus QS-21), AG-707, QS-21 alone, or placebo. Agenus’ QS-21 Stimulon adjuvant is one of the most widely tested vaccine adjuvants under development. For more information, please visit www.agenusbio.com. All patients who received HerpV and were evaluable for immune response showed a statistically significant CD4+ T cell response (100%; 7/7) to HSV-2 antigens as detected by IFNγ Elispot, and the majority of those patients demonstrated a CD8+ T cell response (75%; 6/8).